While the self-renewal capacity of human pluripotent stem cells (hPSCs) allows long-term in vitro culture and the maintenance of multilineage differentiation propensity, self-renewal can also exhibit a darker side. The transplantation of self-renewing hPSCs that "survive" differentiation protocols supposes a risk of tumorigenesis to the patient and, as such, represents a significant "hurdle" to the clinical application of hPSC derivatives [1]. Furthermore, the cancer stem cell (CSC) concept of cancer, in which cells within a tumor acquire the capacity to extensively self-renew and drive tumorigenesis, continues to gain acceptance [2]. Our ability to understand how CSCs arise and self-renew may represent an important step toward treating common and deadly tumors such as hepatocellular carcinoma (HCC). With these concepts in mind, our first Featured Article from Ide et al. describes a means to selectively target and kill undifferentiated hPSCs while, in a related article, Khosla et al. investigate how liver cirrhosis may promote the emergence of self-renewing CSC-like cells associated with HCC development.Another hurdle for the clinical application of hPSC derivatives lies in our understanding of cellular maturity and transplanted cell function. In some cases, such as the treatment of heart disease/damage with hPSC-derived cardiomyocytes (CMs) [3], we currently lack an effective means to generate functionally mature cells that resemble endogenous adult cells. In other cases, such as the treatment of neurological disorders/diseases with hPSC-derived neural cells, we require a better comprehension of which cell along the differentiation spectrum will provide optimal results [4]. Our second Featured Article from Abilez et al. reports a novel means to promote the functional maturity of hPSC-CMs through passive stretch, and in a related article, Qiu et al. identify the optimal maturity of hPSC-derived dopaminergic (DA) neurons required for enhanced functional recovery in a Parkinson's disease (PD) mouse model.